Indivior PLC (LON:INDV – Get Free Report) shares were up 11.9% on Thursday . The stock traded as high as GBX 738 ($9.58) and last traded at GBX 731 ($9.49). Approximately 231,070 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 1,264,178 shares. The stock had previously closed at GBX 653.50 ($8.48).
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,500 ($19.48) price target on shares of Indivior in a research note on Thursday, September 5th.
Read Our Latest Research Report on Indivior
Indivior Stock Performance
Insider Transactions at Indivior
In other Indivior news, insider Jo Le Couilliard bought 1,490 shares of the company’s stock in a transaction on Friday, July 26th. The stock was bought at an average price of GBX 1,006 ($13.06) per share, for a total transaction of £14,989.40 ($19,461.70). 3.44% of the stock is owned by corporate insiders.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
See Also
- Five stocks we like better than Indivior
- How to Invest in Small Cap Stocks
- WD-40 Company Gears Up for a Double-Digit Stock Advance
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Monster and Celsius Energized: Which Stock Offers More Upside?
- Stock Analyst Ratings and Canadian Analyst Ratings
- Sherwin-Williams Plunges Into Buying Opportunity: Time to Buy?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.